Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENZYME - THE KING OF THE BIOTECHS -- Ignore unavailable to you. Want to Upgrade?

To: H. Bradley Toland, Jr. who wrote (325)	7/30/1998 1:06:00 PM
From: Vector1	Read Replies (2) \| Respond to of 410

Brad, I have heard about Genzyme's work with Hurler's. However I had not heard about the study you are describing. Do you have a source? V1

To: H. Bradley Toland, Jr. who wrote (325)	8/2/1998 3:55:00 PM
From: Caveat Emptor	Read Replies (1) \| Respond to of 410

Brad, I'm confused about TRETINOIN Collaboration- Found Info.. I remain confused about the drug TRETINOIN. According to source OAK INVESTMENT PARTNERS, a collaboration agreement exists between ARONEX and GENZYME on this drug. My research has found that TRETINOIN is "Under Investigation for the oral treatment of KAPOSI's SARCOMA, but mentiones nothing about Genzyme Involvement. This drug "all trans-retinoic acid" or TRETINOIN appears to have also been approved for treatment of wrinkles. But this source notes that the drug is commercialized by J&J's Ortho Pharmaceuticals. Does Genzyme have any stake in this drug, as noted on OAKS web site? Does anyone know of the status of the agreement with ARONEX with this drug? My references are: pharminfo.com aegis.com Thank you. CAVEAT EMPTOR